Table S5 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

Liu, Jiahui; Yan, Wenqiang; Fan, Huishou; Xu, Jingyu; Li, Lingna; Du, Chenxing; Mao, Xuehan; Yan, Yuting; Xu, Yan; Sui, Weiwei; Deng, Shuhui; Yi, Shuhua; Anderson, Kenneth C.; Qiu, Lugui; Zou, Dehui; An, Gang

doi:10.1158/2767-9764.24092386.v1

Table S5 from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment

journal contribution

posted on 2023-09-06, 17:38 authored by Jiahui Liu, Wenqiang Yan, Huishou Fan, Jingyu Xu, Lingna Li, Chenxing Du, Xuehan Mao, Yuting Yan, Yan Xu, Weiwei Sui, Shuhui Deng, Shuhua Yi, Kenneth C. Anderson, Lugui Qiu, Dehui Zou, Gang An

Patient and Treatment Characteristics in ASCT cohort: Sustained MRD-negative vs. Sustained MRD-positive

Funding

MOST | National Natural Science Foundation of China (NSFC)

CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine (中国医学科学院创新工程)

History

ARTICLE ABSTRACT

Achieving and maintaining undetectable MRD is the current treatment goal for multiple myeloma. Our results emphasized the remarkable clinical benefit of ASCT on MRD-negative duration, PFS, and OS in patients with multiple myeloma regardless of early MRD status. These favorable impacts were more evident in patients with aggressive features. Importantly, dynamic MRD monitoring among ASCT could facilitate personalized stratification of therapeutic approaches.